Meta-analysis finds 22.5% prevalence of Neisseria gonorrhoeae and high resistance to tetracycline, ciprofloxacin, and penicillin in Kenya

This publication is a systematic review and meta-analysis of epidemiological and antimicrobial resistance data for Neisseria gonorrhoeae. The study was conducted in Kenya and included a total sample size of 5,170 participants. The primary outcome was the pooled prevalence of Neisseria gonorrhoeae and patterns of antimicrobial resistance. The intervention or exposure and comparator were not reported, as this is a synthesis of existing observational data.

The main result for the primary outcome was a pooled prevalence of Neisseria gonorrhoeae of 22.5%, with a 95% confidence interval of 17.2 to 27.8. This finding provides a quantitative estimate of the burden of infection in the studied population. The analysis also reported specific resistance rates for several antimicrobials. The resistance rate for tetracycline was 98.0%, for ciprofloxacin was 96.7%, for penicillin was 94.7%, for azithromycin was 2.0%, for cefixime was 2.6%, and for ceftriaxone was 1.3%.

No key secondary outcomes were reported in the input data. The safety and tolerability findings were also not reported, as adverse events, serious adverse events, discontinuations, and tolerability were all marked as not reported. This absence of safety data is a significant limitation for interpreting the clinical implications of the resistance patterns.

The results can be compared to prior landmark studies and global surveillance reports, which have also documented high levels of resistance to older antibiotics like tetracycline and fluoroquinolones in Neisseria gonorrhoeae. The low resistance rates to azithromycin, cefixime, and ceftriaxone reported here are consistent with current treatment guidelines that recommend these agents as first-line therapies, though the data are specific to the Kenyan context.

Key methodological limitations include that the epidemiological and antimicrobial resistance data are fragmented and under-represent high-risk populations. This suggests potential selection bias and that the pooled prevalence may not be generalizable to all groups in Kenya. The lack of reported intervention or comparator details is inherent to the meta-analysis design, which synthesizes existing studies rather than testing a new therapy.

The clinical implications are that strengthening surveillance, expanding access to reliable diagnostics, and enforcing antibiotic stewardship are critical, as noted in the practice relevance field. Exploration of alternative therapies, including phage therapy, alongside accelerated vaccine research, will be essential for sustainable disease control. However, these are future directions and not direct results of this meta-analysis.

Key questions that remain unanswered include the specific populations under-represented in the data, the temporal trends of resistance, and the clinical outcomes associated with these resistance patterns, such as treatment failure rates. The absence of safety data also leaves unanswered questions about the tolerability of current regimens in this population.